Coverage is not payment. This single misunderstanding has distorted clinical trial financing for nearly a generation.
For more than two decades, research institutions have relied on Coverage Analyses to distinguish health insurance-billable routine costs from sponsor-obligated research expenses. This book argues that the Coverage Analysis, while essential for complying with anti-fraud laws, has been misapplied as a budgeting tool in recent years, and that the resulting coverage-centric model of clinical trial financing is no longer tenable for research hospitals under current insurance reimbursement methodologies. The Coverage Analysis remains a critical compliance tool for managing research patient charges but changes in health insurance reimbursement have made the tool outdated as a basis for financing.
Drawing on the Medicare Outpatient Prospective Payment System (OPPS) and frameworks established in the U.S. Supreme Court's Escobar and SuperValu cases, the authors demonstrate widespread misalignment of clinical research financial processes—resulting in losses to research sites and increased legal risk. At the heart of the problem is a widely held but empirically false assumption: that insurance coverage equates to insurance payment. Under OPPS, many services Medicare technically "covers" receive minimal or no separate payment, imposing hidden losses on institutions and unanticipated out-of-pocket costs for research patients.
The book advances a new payment-centric model anchored by the Research Payment Analysis (RPA)—a methodological innovation that replaces coverage determinations with empirical reimbursement data as the foundation for sponsor budget negotiations. The book argues that the RPA offers a better opportunity than a Coverage Analysis for research sites to recoup their costs through industry sponsor budget negotiations, improve time-to-activation for trials, and be on a stronger compliance footing.
Clinical Research & Health Insurance has been written for clinical research administrators, hospital revenue cycle professionals, health care lawyers, and compliance officers as well as anyone else seeking a rigorous framework for understanding the intersection of law and clinical trial financing.
"synopsis" may belong to another edition of this title.
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: New. Seller Inventory # 53658699-n
Seller: California Books, Miami, FL, U.S.A.
Condition: New. Seller Inventory # I-9798994985212
Seller: GreatBookPrices, Columbia, MD, U.S.A.
Condition: As New. Unread book in perfect condition. Seller Inventory # 53658699
Seller: Grand Eagle Retail, Bensenville, IL, U.S.A.
Paperback. Condition: new. Paperback. Coverage is not payment. This single misunderstanding has distorted clinical trial financing for nearly a generation. For more than two decades, research institutions have relied on Coverage Analyses to distinguish health insurance-billable routine costs from sponsor-obligated research expenses. This book argues that the Coverage Analysis, while essential for complying with anti-fraud laws, has been misapplied as a budgeting tool in recent years, and that the resulting coverage-centric model of clinical trial financing is no longer tenable for research hospitals under current insurance reimbursement methodologies. The Coverage Analysis remains a critical compliance tool for managing research patient charges but changes in health insurance reimbursement have made the tool outdated as a basis for financing. Drawing on the Medicare Outpatient Prospective Payment System (OPPS) and frameworks established in the U.S. Supreme Court's Escobar and SuperValu cases, the authors demonstrate widespread misalignment of clinical research financial processes-resulting in losses to research sites and increased legal risk. At the heart of the problem is a widely held but empirically false assumption: that insurance coverage equates to insurance payment. Under OPPS, many services Medicare technically "covers" receive minimal or no separate payment, imposing hidden losses on institutions and unanticipated out-of-pocket costs for research patients. The book advances a new payment-centric model anchored by the Research Payment Analysis (RPA)-a methodological innovation that replaces coverage determinations with empirical reimbursement data as the foundation for sponsor budget negotiations. The book argues that the RPA offers a better opportunity than a Coverage Analysis for research sites to recoup their costs through industry sponsor budget negotiations, improve time-to-activation for trials, and be on a stronger compliance footing. Clinical Research & Health Insurance has been written for clinical research administrators, hospital revenue cycle professionals, health care lawyers, and compliance officers as well as anyone else seeking a rigorous framework for understanding the intersection of law and clinical trial financing. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Seller Inventory # 9798994985212
Seller: PBShop.store US, Wood Dale, IL, U.S.A.
PAP. Condition: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L0-9798994985212
Seller: PBShop.store UK, Fairford, GLOS, United Kingdom
PAP. Condition: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000. Seller Inventory # L0-9798994985212
Quantity: Over 20 available
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: New. Seller Inventory # 53658699-n
Quantity: Over 20 available
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Condition: As New. Unread book in perfect condition. Seller Inventory # 53658699
Quantity: Over 20 available
Seller: CitiRetail, Stevenage, United Kingdom
Paperback. Condition: new. Paperback. Coverage is not payment. This single misunderstanding has distorted clinical trial financing for nearly a generation. For more than two decades, research institutions have relied on Coverage Analyses to distinguish health insurance-billable routine costs from sponsor-obligated research expenses. This book argues that the Coverage Analysis, while essential for complying with anti-fraud laws, has been misapplied as a budgeting tool in recent years, and that the resulting coverage-centric model of clinical trial financing is no longer tenable for research hospitals under current insurance reimbursement methodologies. The Coverage Analysis remains a critical compliance tool for managing research patient charges but changes in health insurance reimbursement have made the tool outdated as a basis for financing. Drawing on the Medicare Outpatient Prospective Payment System (OPPS) and frameworks established in the U.S. Supreme Court's Escobar and SuperValu cases, the authors demonstrate widespread misalignment of clinical research financial processes-resulting in losses to research sites and increased legal risk. At the heart of the problem is a widely held but empirically false assumption: that insurance coverage equates to insurance payment. Under OPPS, many services Medicare technically "covers" receive minimal or no separate payment, imposing hidden losses on institutions and unanticipated out-of-pocket costs for research patients. The book advances a new payment-centric model anchored by the Research Payment Analysis (RPA)-a methodological innovation that replaces coverage determinations with empirical reimbursement data as the foundation for sponsor budget negotiations. The book argues that the RPA offers a better opportunity than a Coverage Analysis for research sites to recoup their costs through industry sponsor budget negotiations, improve time-to-activation for trials, and be on a stronger compliance footing. Clinical Research & Health Insurance has been written for clinical research administrators, hospital revenue cycle professionals, health care lawyers, and compliance officers as well as anyone else seeking a rigorous framework for understanding the intersection of law and clinical trial financing. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability. Seller Inventory # 9798994985212
Quantity: 1 available